Articles tagged with Breast Cancer
A meta-analysis of large randomised trials found no significant increase in cancer risk among those taking daily folic acid for 5 years or less. The study provides reassurance about the safety of folic acid intake, particularly in countries where fortification is mandatory.
A prospective study of 1,200 healthy women found that low serum vitamin D levels before diagnosis increased the risk of premenopausal breast cancer. Women with low vitamin D levels had approximately three times the risk of breast cancer as those in the highest vitamin D group.
A study of 20 cohort studies found that high fruit and vegetable intake was associated with a lower risk of estrogen receptor-negative (ER-) breast cancer. The results suggest that increasing vegetable consumption may help lower ER- breast cancer risk, which accounts for only 15-20% of breast cancers.
Researchers found that combining PI3K inhibitors with anti-HER2 therapy can prolong treatment effectiveness by targeting the PI3K pathway, which activates anti-death protein survivin. High levels of survivin correlate with resistance to therapy, suggesting its measurement could predict treatment outcomes.
Researchers have identified a link between SNPs associated with breast cancer risk and the binding affinity of pioneer factor FOXA1. The study found that most risk-associated SNPs modulate FOXA1 binding, which is crucial for chromatin opening and transcription factor recruitment.
Researchers at Saint Louis University have discovered a molecular pathway contributing to triple-negative breast cancer and identified vitamin D as a possible new therapy. They also found three biomarkers to identify patients who could benefit from treatment, which may lead to less toxic therapeutic strategies.
Large-scale genomic sequencing reveals two DNA mutations driving 15% of meningiomas, a type of slow-growing brain tumor. The findings suggest targeted therapies may provide an effective treatment option for these patients.
Researchers at LSUHSC have identified a new therapeutic target to block the function of Her2, a gene that promotes breast cancer progression and spread. The study also found that a novel protein called Nischarin regulates breast cancer cell migration and movement.
The American Cancer Society's annual report shows a 20% decrease in cancer mortality rates since 1991, with significant drops in lung, colorectal, breast, and prostate cancers. These declines are attributed to reductions in smoking and improvements in early detection and treatment.
A new study in Spain found that breast cancer mortality among women under 50 has decreased, but among those over 85, it has remained stable. The researchers suggest adapting preventative practices according to patient age to improve outcomes.
Researchers identified a genetic marker in over 300 women with breast cancer, finding that those with this marker were more likely to experience recurrence. This breakthrough could enable doctors to tailor treatment strategies for high-risk patients based on their unique genetic profiles.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
Fox Chase Cancer Center has received a grant to expand its community-based patient navigation services, which will help women with abnormal mammography results obtain follow-up care. The grant also supports 10 breast cancer education programs in the community and provides mammography screening services for under-insured women.
Researchers at Fox Chase Cancer Center found that the NEDD9 gene controls the growth of progenitor cells that give rise to tumors, suggesting a new approach to treating breast cancer. The study also identified a link between NEDD9 levels and sensitivity to certain drugs.
A Weill Cornell study reveals that a specific miRNA, miR-708, acts as a metastatic tumor inhibitor and can be restored to stop the spread of aggressive breast cancer. Synthetic miR-708 delivery has blocked metastatic outgrowth in mice, making it a promising therapeutic target.
Dr. Nicholas Navin's new approach to genetic analysis could help researchers understand and map the complex process of cancer evolution, ultimately blocking the spread of cancer to other organs. The project aims to identify important mutations in single tumor cells at various stages of cancer development.
Researchers at Duke University Medical Center have developed a way to deploy sickle-shaped red blood cells to fight cancer tumors by exploiting their ability to adhere to and block the blood vessels surrounding hypoxic tumors. The treatment causes tumor cell death through oxidative stress, resulting in delayed tumor growth.
A new study by Oregon State University researchers reveals that Hmong women often make their own health decisions, but in an environment where screening is not discussed. The study found higher rates of breast and cervical cancer screenings among the Hmong population compared to national averages.
A recent study published in The BMJ suggests that cancer screening for patients with a life expectancy of less than 10 years may not be beneficial. The researchers analyzed data from five breast and four colorectal cancer trials, finding that the benefits of screening often outweigh the risks. However, they also emphasize that individu...
A recent study published in JAMA Internal Medicine found that higher spending on breast cancer screenings does not result in improved outcomes for older women. The research team analyzed Medicare expenditures and screened female beneficiaries over two years, discovering substantial geographic variation in costs.
New research reveals that 18F-FDG PET/CT provides better prognostic information than conventional imaging, changing management for over 50% of patients. The study found that PET/CT accurately identified lesions in multiple areas, leading to revised staging and treatment plans.
A recent study found that tumor boards have a modest association with the types of treatments patients receive for certain cancers. For example, lung cancer and prostate cancer patients were more likely to receive higher-quality care when treated at hospitals with tumor boards. However, other types of cancer care remained unaffected by...
A recent study published in PLOS Biology has discovered the role of ELF5 in aggressive breast cancer subtypes and its potential to overcome anti-estrogen therapies. The research suggests that manipulating ELF5 levels could lead to new treatment strategies for breast cancer patients.
A new study reveals how a 'transcription factor' called ELF5 causes aggressive breast cancer to develop, making it resistant to oestrogen therapies. Researchers found that manipulating ELF5 levels could be a potential treatment option for this type of breast cancer.
A new study by researchers from the Mayo Clinic and Austrian Breast and Colorectal Cancer Study Group found that genetic differences in liver enzyme CYP2D6 play a key role in tamoxifen's effectiveness. Women with altered CYP2D6 enzyme activity had higher rates of breast cancer recurrence and death, while those with normal enzyme activi...
A nationwide prospective cohort study found that offspring of cancer patients diagnosed at older ages are still at higher risk of developing the same cancer. The study suggests a significant genetic component to familial risks, with increased risks observed for various cancers including non-Hodgkin lymphoma, breast, and prostate cancer.
A recent study by Vall d'Hebron Institute of Oncology has led to the redefinition of hormone-sensitive breast tumours, improving diagnosis and treatment outcomes. Gene expression analysis revealed discrepancies between histopathological data and molecular profiles, prompting a new definition that incorporates progesterone receptor levels.
A study by the University of Colorado Anschutz Medical Campus suggests that a healthy lifestyle during menopause, including diet and exercise, can lower breast cancer risk. In obese postmenopausal women, excess calories fuel tumor growth, but in lean counterparts, they are stored in healthy tissues.
Researchers identified ID proteins as regulators of glioma progression and potential therapeutic targets. In contrast, the loss of TREM-1 increased inflammation and worsened lung infection outcomes in mice. Additionally, breast cancer cells interact with stroma to drive metastasis through HIF-dependent signaling pathways.
Researchers identified miR-181a as a molecule linked to aggressive breast cancer forms. Elevated levels of miR-181a prevented metastasis and extended mouse lifespans in test models.
Scientists have developed a new magnetic resonance imaging (MRI) method to evaluate the cellular proliferation of breast cancer tumor models. This non-invasive technique assesses water diffusion in tumor tissue, correlating it with growth rates.
Changes in progenitor cell populations in breast tissue may contribute to breast cancer development, according to new research. The study found that aging leads to a decrease in myoepithelial cells and an increase in multipotent progenitors, which can fuel malignant growth.
A preclinical study suggests that inhibiting mTORC1 with everolimus can suppress Myc-driven tumor initiation and growth. Everolimus caused tumor regression by inducing cellular senescence, rather than apoptosis.
Researchers discovered HER2-positive breast cancer stem cells in previously thought HER2-negative tumors, making these cells resistant to traditional treatments. The findings suggest that targeted therapies can effectively treat HER2-negative breast cancers, while also providing a new diagnostic tool.
A new hormone therapy combining conventional estrogen with a bone-protective SERM-like drug has shown promise in reducing menopausal symptoms and osteoporosis risk without increasing breast cancer risk. The treatment approach, termed TSEC, was tested in postmenopausal nonhuman primates over a 20-month period.
A large study finds that post-menopausal breast cancer survivors are more likely to develop diabetes, with a significant association observed after chemotherapy. The risk increases over time, suggesting the need for closer monitoring and screening of these patients.
A study published in Breast Cancer Research and Treatment found that delaying childbirth for at least 15 years after the first menstrual period can reduce the risk of triple-negative breast cancer by up to 60%. Breastfeeding is also associated with a protective effect against this aggressive form of breast cancer.
Researchers at Fox Chase Cancer Center developed a novel 3D culture system to mimic the environment surrounding IBC cells. The model showed that the tumor microenvironment promotes proliferation, growth and invasion of IBC tumors.
Scientists discovered blocking a specific protein makes tumors more vulnerable to treatment in mice, hinting at potential new therapies for humans. Researchers are now exploring inhibitors of the protein, which could boost cancer drugs' effectiveness.
A preclinical study published in Cancer Research found that obesity and overfeeding during menopause together drive aggressive tumor growth and progression. Obesity-related metabolic changes allowed breast tumors to accumulate glucose and promote proliferation.
Researchers found that Mesupron combined with Capecitabine significantly extended progression-free survival for patients with metastatic breast cancer to 8.3 months, nearly twice that of those taking Capecitabine alone. The study also showed improved results in previously treated patients.
A study by Vanderbilt-Ingram Cancer Center investigators found that most triple-negative breast cancer patients have multiple genetic mutations, despite treatment with chemotherapy. The research may provide targets for new therapies and shed light on the challenges of treating this form of cancer.
A Mayo Clinic study discovered 27 genes associated with a good outcome using concurrent trastuzumab and chemotherapy, while five genes linked to poor outcomes. The findings aim to develop a genetic test to select the best treatment for HER2-positive patients.
A phase III clinical trial compared eribulin mesylate to capecitabine in women with previously treated metastatic breast cancer, showing a trend towards improved overall survival. The median overall survival was 15.9 months for eribulin and 14.5 months for capecitabine.
Researchers found that some women with HER2 negative breast cancer may still benefit from anti-HER2 drugs due to undetected mutations. The study identified 25 patients with HER2 mutations without amplification, and most responded well to treatment. A phase II clinical trial is now underway to test the effectiveness of these treatments.
A pooled analysis of eight cohort studies found that women with higher circulating carotenoid levels had statistically significantly lower breast cancer risk. The inverse association was strongest for estrogen receptor-negative (ER-) breast cancers, highlighting carotenoids as a potential modifiable risk factor.
A study by TGen and US Oncology Research identified genetic mutations in 14 metastatic TNBC patients, including TP53 and ERBB4 tumor suppressor genes. The research offers potential drug targets for this aggressive form of breast cancer.
Research from Fox Chase Cancer Center finds that women are more likely to follow experts' advice on reducing risk of lymphedema after breast cancer surgery if they feel confident in their abilities and know how to manage stress. Women who feel empowered can modify their behavior to avoid the complication, whereas daily behavioral chang...
A groundbreaking clinical trial reveals that women with estrogen receptor-positive breast cancer who take tamoxifen for 10 years have a lower risk of recurrence and mortality rate compared to those taking the drug for 5 years. This new finding may prompt patients to reconsider their treatment options, particularly premenopausal women.
Researchers found that statin use improved progression-free survival and disease-specific survival in patients with stage III inflammatory breast cancer. Patients who took hydrophilic statins saw the greatest improvement in survival, with an average of 4.88 years.
A new study conducted by Mayo Clinic reveals that sentinel lymph node surgery can accurately identify residual breast cancer in lymph nodes after chemotherapy, with a success rate of 91%. The procedure removed only a few lymph nodes, reducing surgical complications, and found complete eradication of cancer in 40% of patients.
Researchers found that continuing tamoxifen treatment beyond 5 years further reduced breast cancer recurrence and mortality rates. The additional benefits took some years to emerge, with risks of recurrence decreasing from 21.4% at year 15 in those who continued treatment compared to 25.1% in controls.
African American women with early-stage invasive breast cancer were 12% less likely to receive the minimally invasive axillary sentinel lymph node biopsy compared to Caucasian women. The study found higher rates of lymphedema among African American women who underwent the older, more invasive procedure.
Researchers at the UNM Cancer Center are studying GPER, a novel estrogen receptor, to develop potential therapies for breast cancer. By understanding how GPER influences tumor growth and metastasis, they aim to create more effective treatments that can reduce resistance to existing drugs.
A series of studies by Intermountain Healthcare's Oncology Clinical Program shows that improving care across a large hospital system is possible through standardized care. Key findings include reduced mastectomies and lymph node removals in breast cancer patients, indicating a more consistent approach to treatment.
A new genetic test can accurately identify the presence of breast cancer tumors and predict the progression of tumor development. This breakthrough technology analyzes genetic switches to detect cancer growth, enabling earlier diagnosis and more effective treatment plans.
A study at Thomas Jefferson University found that meditation paired with art therapy significantly reduced stress and anxiety in women with breast cancer. The treatment altered brain activity, increasing emotional centers associated with positive emotions, stress regulation, and reward system function.
Women with advanced breast cancer who wait over 60 days for treatment face significantly higher risks of dying. Early detection and timely treatment can increase five-year survival rates to as high as 98 percent.
Kornelia Polyak and Mina J. Bissell will receive the AACR Outstanding Investigator Award for Breast Cancer Research and Distinguished Lectureship, respectively. The symposium presents a balance of clinical, translational, and basic research on breast cancer.
A study found that DCIS patients with combined RB and PTEN loss are at high risk of progressing to invasive breast cancer. Women lacking both genes are over 5 times more likely to develop invasive breast cancer.